HCW Biologics Regains Nasdaq Bid Price Compliance, Implements 1-for-6 Reverse Split
HCWB has more than doubled off its 52-week low of $0.25.
Summary
HCW Biologics announced it has regained compliance with Nasdaq's minimum bid price rule, effective with a 1-for-6 reverse stock split. The company will be subject to a mandatory monitoring period.
Key Events · Corporate Governance and Compliance · HCWB
-
Regained Nasdaq Compliance
The company received notice that it has regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)), resolving a previous deficiency.
-
Reverse Stock Split Effected
A 1-for-6 reverse stock split was effected on June 30, 2026, to ensure long-term compliance with the bid price requirement, following shareholder approval on June 15, 2026.
-
Mandatory Monitoring Period Imposed
HCW Biologics will be subject to a mandatory Nasdaq Panel Monitor until June 17, 2027. During this period, any future non-compliance with the bid price rule will result in an immediate delisting determination without further opportunity to cure.
Analysis · HCWB · Life Sciences
HCW Biologics has successfully resolved its Nasdaq bid price deficiency, removing an immediate delisting threat. This was achieved through a 1-for-6 reverse stock split, which was previously approved by shareholders. While regaining compliance is positive for maintaining market access, the company will be under a mandatory monitoring period until June 2027, with no further grace period if it falls out of compliance with the bid price rule again.
At the time of this filing, HCWB was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.25 to $7.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.